

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 March 2023 (30.03.2023)



(10) International Publication Number
WO 2023/049742 A2

- (51) **International Patent Classification:**
C12N 15/113 (2010.01) C12N 9/22 (2006.01)
- (21) **International Application Number:**
PCT/US2022/076774
- (22) **International Filing Date:**
21 September 2022 (21.09.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/246,543 21 September 2021 (21.09.2021) US
63/321,517 18 March 2022 (18.03.2022) US
- (71) **Applicant: SCRIBE THERAPEUTICS INC.** [US/US];
1150 Marina Village Parkway, Alameda, California 94501 (US).
- (72) **Inventors: FERNANDES, Jason;** c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **WHITE, Ross;** c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **HIGGINS, Sean;** c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **DENNY, Sarah;** c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501

(US). **OAKES, Benjamin;** c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US). **CHARLES, Emeric Jean Marius;** c/o Scribe Therapeutics Inc., 1150 Marina Village Parkway, Alameda, California 94501 (US).

(74) **Agent: CANDE, Jessica D.** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) **Title:** ENGINEERED CASX REPRESSOR SYSTEMS

FIG. 44A

Specificity/Activity with
ELXR-ZIM3 for spacer 7.165



(57) **Abstract:** The disclosure relates to gene repressor systems comprising catalytically-dead Class 2 CRISPR proteins and one or more transcription repressor domains linked to the catalytically-dead Class 2 CRISPR protein as a fusion protein, as well as a guide ribonucleic acid (gRNA); and methods of making and using same.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*